Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases

Journal of Molecular Diagnostics

Volumn 16, Issue 5, 2014, Pages 558-563

  Yang, Haihong ^a   Cai, Linbo ^c   Zhang, Yalei ^a   Tan, Hongyu ^b   Deng, Qiuhua ^a   Zhao, Meiling ^a   Xu, Xin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b The First Affiliated Hospital   (China)

^c Guangdong 999 Brain Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; AMPLIFICATION REFRACTORY MUTATION SYSTEM POLYMERASE CHAIN REACTION; ARTICLE; BRAIN METASTASIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; EXON; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HUMAN; INTRACRANIAL TUMOR; LUNG ADENOCARCINOMA; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIMARY TUMOR; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; BRAIN NEOPLASMS; CEREBROSPINAL FLUID; GENETIC SCREENING; GENETICS; GENOTYPING TECHNIQUE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY; STANDARDS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; GENETIC TESTING; GENOTYPING TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84906232643     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2014.04.008     Document Type: Article

References (17)

1. L.J. Hazard, R.L. Jensen, and D.C. Shrieve Role of stereotactic radiosurgery in the treatment of brain metastases Am J Clin Oncol 28 2005 403 410
2. R. Soffietti, P. Cornu, J.Y. Delattre, R. Grant, F. Graus, W. Grisold, J. Heimans, J. Hildebrand, P. Hoskin, M. Kalljo, P. Krauseneck, C. Marosi, T. Siegal, and C. Vecht EFNS Guidelines on diagnosis and treatment of brain metastases: report of EFNS Task Force Eur J Neurol 13 2006 674 681
3. M. Shingyoji, H. Kageyama, T. Sakaida, T. Nakajima, Y. Matsui, M. Itakura, T. Iuchi, S. Yokoi, H. Kimura, and T. Iizasa Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis J Thorac Oncol 6 2011 1215 1220
4. J.E. Kim, D.H. Lee, Y. Choi, D.H. Yoon, S.W. Kim, C. Suh, and J.S. Lee Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis Lung Cancer 65 2009 351 354
5. R. Porta, J.M. Sánchez-Torres, L. Paz-Ares, B. Massutí, N. Reguart, C. Mayo, P. Lianes, C. Queralt, V. Guillem, P. Salinas, S. Catot, D. Isla, A. Pradas, A. Gúrpide, J. de Castro, E. Polo, T. Puig, M. Tarón, R. Colomer, and R. Rosell Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Eur Respir J 37 2011 624 631
6. C. Xue, Z. Hu, W. Jiang, Y. Zhao, F. Xu, Y. Huang, J. Wu, Y. Zhang, L. Zhao, J. Zhang, L. Chen, and L. Zhang National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China Lung Cancer 77 2012 371 375
7. C.H. Rhodes, C. Honsinger, and G.D. Sorenson Detection of tumor-derived DNA in cerebrospinal fluid J Neuropathol Exp Neurol 53 1994 364 368
8. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, and J. Verweij New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
9. G. Ellison, E. Donald, G. McWalter, L. Knight, L. Fletcher, J. Sherwood, M. Cantarini, M. Orr, and G. Speake A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples J Exp Clin Cancer Res 29 2010 132
10. B. Angulo, E. Conde, A. Suárez-Gauthier, C. Plaza, R. Martínez, P. Redondo, E. Izquierdo, B. Rubio-Viqueira, L. Paz-Ares, M. Hidalgo, and F. López-Ríos A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry PLos One 7 2012 e43842
11. S.E. Monaco, M.N. Nikiforova, K. Cieply, L.A. Teot, W.E. Khalbuss, and S. Dacic A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases Hum Pathol 41 2010 94 102
12. C. Han, J. Ma, J. Zhao, Y. Zhou, W. Jing, and H. Zou EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis Cancer Invest 29 2011 626 634
13. B. Weber, M. Winterdahl, A. Memon, B.S. Sorensen, S. Keiding, L. Sorensen, E. Nexo, and P. Meldgaard Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor J Thorac Oncol 6 2011 1287 1289
14. Y.L. Wu, C. Zhou, Y. Cheng, S. Lu, G.Y. Chen, C. Huang, Y.S. Huang, H.H. Yan, S. Ren, Y. Liu, and J.J. Yang Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803) Ann Oncol 24 2013 993 999
15. M.C. Chamberlain Neoplastic meningitis Neurologist 12 2006 179 187
16. M. Brevet, M.L. Johnson, C.G. Azzoli, and M. Ladanyi Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors Lung Cancer 73 2011 96 102
17. X. Zhang, Y. Zhao, M. Wang, W.S. Yap, and A.Y. Chang Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer Lung Cancer 60 2008 175 182